Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
OPA1-03189 detects phosphorylated VEGFR2 (pTyr1054) from mouse samples and is expected to react with rat samples.
OPA1-03189 has been successfully used in Western blot procedures. By Western blot, this antibody detects a ~190 kDa protein representing phospho-VEGFR2 (pTyr1054).
OPA1-03189 immunizing phosphopeptide was derived from a region of human VEGFR2 that contains tyrosine 1054.
KDR (FLK1, VEGFR2) is a type III receptor tyrosine kinase. It binds vascular endothelial growth factor with high affinity in vitro, and is expressed early in development by endothelial cell precursors. FLK1 (VEGF Receptor 2) encodes one of the two receptors of the VEGF. This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc. Mutations of FLK1 (VEGF Receptor 2) are implicated in infantile capillary hemangiomas.
仅用于科研。不用于诊断过程。未经明确授权不得转售。